185 related articles for article (PubMed ID: 35019731)
21. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
[TBL] [Abstract][Full Text] [Related]
22. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
Rammohan K; Coyle PK; Sylvester E; Galazka A; Dangond F; Grosso M; Leist TP
Drugs; 2020 Dec; 80(18):1901-1928. PubMed ID: 33247831
[TBL] [Abstract][Full Text] [Related]
23. Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
Giovannoni G; Singer BA; Issard D; Jack D; Vermersch P
Mult Scler; 2022 Jul; 28(8):1219-1228. PubMed ID: 34634968
[TBL] [Abstract][Full Text] [Related]
24. Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis.
Hermann R; Litwin JS; Friberg LE; Dangond F; Munafo A
Br J Clin Pharmacol; 2019 Jul; 85(7):1484-1494. PubMed ID: 30883839
[TBL] [Abstract][Full Text] [Related]
25. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
Brochet B; Solari A; Lechner-Scott J; Piehl F; Langdon D; Hupperts R; Selmaj K; Patti F; Brieva L; Maida EM; Alexandri N; Smyk A; Nolting A; Keller B; Montalban X; Kubala Havrdova E
Mult Scler; 2023 Dec; 29(14):1808-1818. PubMed ID: 37978852
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
[TBL] [Abstract][Full Text] [Related]
27. Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.
Giovannoni G; Coyle PK; Vermersch P; Walker B; Aldridge J; Nolting A; Galazka A; Lemieux C; Leist TP
Front Immunol; 2021; 12():763433. PubMed ID: 35003076
[TBL] [Abstract][Full Text] [Related]
28. Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis.
Oh J; Walker B; Giovannoni G; Jack D; Dangond F; Nolting A; Aldridge J; Lebson LA; Leist TP
Mult Scler J Exp Transl Clin; 2021; 7(3):20552173211024298. PubMed ID: 34345436
[TBL] [Abstract][Full Text] [Related]
29. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study.
Freedman MS; Leist TP; Comi G; Cree BA; Coyle PK; Hartung HP; Vermersch P; Damian D; Dangond F
Mult Scler J Exp Transl Clin; 2017; 3(4):2055217317732802. PubMed ID: 29051829
[TBL] [Abstract][Full Text] [Related]
31. Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.
de Stefano N; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Roy S;
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35701185
[TBL] [Abstract][Full Text] [Related]
32. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
Meuth SG; Bayas A; Kallmann B; Kleinschnitz C; Linker R; Rieckmann P; Mäurer M
Expert Opin Pharmacother; 2020 Nov; 21(16):1965-1969. PubMed ID: 32658554
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
[TBL] [Abstract][Full Text] [Related]
34. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
35. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
Comi G; Cook SD; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett AC; Viglietta V; Greenberg SJ
J Neurol; 2013 Apr; 260(4):1136-46. PubMed ID: 23263473
[TBL] [Abstract][Full Text] [Related]
36. Development of oral cladribine for the treatment of multiple sclerosis.
Hartung HP; Aktas O; Kieseier B; Giancarlo Comi GC
J Neurol; 2010 Feb; 257(2):163-70. PubMed ID: 19921304
[TBL] [Abstract][Full Text] [Related]
37. Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.
Bell Gorrod H; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
Adv Ther; 2020 Jan; 37(1):225-239. PubMed ID: 31701485
[TBL] [Abstract][Full Text] [Related]
38. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
Gorrod HB; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
Value Health; 2019 Jul; 22(7):772-776. PubMed ID: 31277823
[TBL] [Abstract][Full Text] [Related]
39. Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety.
Moser T; Ziemssen T; Sellner J
Wien Med Wochenschr; 2022 Nov; 172(15-16):365-372. PubMed ID: 35451662
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
Pinheiro B; Guerreiro R; Costa J; Miguel LS
J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
